Wyeth Mylotarg Safety Profile Supports Use In Patients 60 - Advisory Cmte.
Executive Summary
Wyeth's treatment for relapsed acute myeloid leukemia patients Mylotarg was recommended for accelerated approval in patients 60 years and older by FDA's Oncologic Drugs Advisory Committee March 17.